Compare YieldMax NVDA Option Income Strategy ETF (NVDY) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax NVDA Option Income Strategy ETF vs Pfizer Inc — how do they compare? YieldMax NVDA Option Income Strategy ETF trades at $12.79 (market cap $1.46B), while Pfizer Inc trades at $27.78 (market cap $159.59B). The key difference: Pfizer Inc is far larger — about 109.3× YieldMax NVDA Option Income Strategy ETF's market cap, and Pfizer Inc pays a 6.14% dividend while YieldMax NVDA Option Income Strategy ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold YieldMax NVDA Option Income Strategy ETF for 43 Days and Pfizer Inc for 158 Days on average.
| NVDY | PFE | |
|---|---|---|
Market Cap | $1.46B | $159.59B |
Volume | 1,111,033 | 30,937,010 |
Sector | Income / Options Overlay | Health |
52-Week High | $17.21 | $29.02 |
52-Week Low | $11.58 | $23.67 |
Typical Hold Time | 43 Days | 158 Days |
Enterprise Value | — | $211.09B |
Dividend Yield | — | 6.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVDY trades at $13.01, down 0.31% on the day, with a bullish technical signal from moving averages but neutral oscillators. The ETF generates weekly dividends, averaging around $0.10 per share recently, reflecting its income-focused strategy tied to NVIDIA's stock volatility. However, key valuation ratios like P/E and P/S are unavailable, limiting fundamental clarity.
The outlook is mixed: strong dividend yields appeal to income seekers, but structural caps on upside participation and potential NAV erosion pose long-term risks. Analyst sentiment has shifted to hold due to declining volatility in NVIDIA, suggesting cautious optimism for income but limited growth potential.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About YieldMax NVDA Option Income Strategy ETF
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
